A multi-centre, randomized, double blind, parallel group study to investigate efficacy and safety of ONO-5334 in postmenopausal women with osteopenia or osteoporosis.
Phase of Trial: Phase II
Latest Information Update: 02 Dec 2016
At a glance
- Drugs ONO 5334 (Primary) ; Alendronic acid
- Indications Bone resorption; Postmenopausal osteoporosis
- Focus Biomarker; Therapeutic Use
- Acronyms OCEAN
- 31 Aug 2018 Biomarkers information updated
- 05 Dec 2012 Planned number of patients changed from 265 to 285 as reported by European Clinical Trials Database record.
- 24 Mar 2012 Quantitative computed tomography results presented at the 2012 IOF World Congress on Osteoporosis and 11th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History